Related Experiment Video
Updated: Aug 10, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Valproic acid and HIV-1 latency: beyond the sound bite
1Department of Medicine, Saint Michael's Medical Center, The New Jersey Medical School, Newark, New Jersey 07102, USA. ssmith1824@aol.com
Researchers explored a potential HIV cure using valproic acid and enfuvirtide. This combination therapy may reduce the latent HIV-1 reservoir in CD4+ T-cells, offering new hope for HIV infection treatment.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- HIV-1 infection establishes a latent reservoir in CD4+ T-cells.
- The viral reservoir is a major barrier to HIV cure.
- Novel therapeutic strategies are needed to target latent HIV-1.
Purpose of the Study:
- To critically evaluate the potential of valproic acid plus enfuvirtide in reducing the HIV-1 latent reservoir.
- To assess the implications of recent findings on HIV curability.
Main Methods:
- Pilot study utilizing valproic acid and enfuvirtide.
- Analysis of CD4+ T-cell pool and latent HIV-1 reservoir.
- Critical review of published data.
Main Results:
- Valproic acid and enfuvirtide combination therapy demonstrated a reduction in the pool of latently HIV-1 infected CD4+ T-cells.
- The study suggests a potential pathway towards reducing the viral reservoir.
Conclusions:
- The findings offer a promising avenue for HIV cure research.
- Further investigation is warranted to confirm and expand upon these results for effective HIV eradication.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Inhibitors of Virion Maturation and Assembly

